EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice

Khalid M Al Naamani iD, Sundus Rizwan, Siham Al Sinani, Bader Al Rawahi iD, Sheikha AlMa'mari, Mohamed El-Kassas

Clinical and Applied Thrombosis/Hemostasis · 2026

DOI: 10.1177/10760296261420229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2026. Verfasst von Khalid M Al Naamani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology & Hepatology, The Medical City for Military and Security Services, Muscat, Oman. Hauptthemen laut MEDLINE: Venous Thrombosis, Liver Cirrhosis, Portal Vein, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemostasis in cirrhosis is a dynamic, “rebalanced” state rather than a simple bleeding diathesis. Portal vein thrombosis (PVT) is a frequent complication linked to variceal bleeding, hepatic decompensation, and mortality. Anticoagulation can prevent thrombus progression, promote recanalization, and improve survival without a major increase in bleeding risk.

Objectives

To summarize the safety, efficacy, and pharmacologic considerations of direct oral anticoagulants (DOACs) for PVT in cirrhosis.

Methods

This narrative review is informed by a systematic literature search (Ovid Medline, Ovid EMBASE, Cochrane Central, Cochrane Database of Systematic Reviews, and Scopus) from 2010 to 17 July 2025. We included cohort, interventional, and meta-analytic studies evaluating DOACs in adults with cirrhosis and PVT, and synthesized these with pharmacokinetic data and international guidance.

Results

Fixed-dose oral DOACs, with generally favorable safety profiles, are promising alternatives to vitamin K antagonists (VKAs) and low-molecular-weight heparins. Regulatory guidance supports DOAC use in Child–Turcotte–Pugh (CTP) class A, recommends cautious use in selected CTP class B patients, and generally discourages use in CTP class C. Apixaban and edoxaban show relatively stable pharmacokinetics in compensated cirrhosis. Observational cohorts and network meta-analyses suggest that DOACs achieve at least comparable, and often higher, rates of portal vein recanalization than VKAs, with similar risks of major and variceal bleeding.

Conclusions

Overall, DOACs represent an effective and convenient anticoagulation option for carefully selected cirrhotic patients with PVT. Treatment should be individualized according to liver and renal function, variceal status, and transplant candidacy. High-quality prospective studies are still needed, particularly in CTP classes B/C cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThrombosisLiver CirrhosisPortal VeinAnticoagulantsHumansAdministration, Oral

Stichwörter der Autor:innen

Child–Turcotte–Pugh Classcirrhosisdirect oral anticoagulantsportal vein thrombosisthrombosis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Gastroenterology & Hepatology, The Medical City for Military and Security Services, Muscat, Oman.
  • Steatotic Liver Disease Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt.
  • Department of Child Health, Sultan Qaboos University Hospital, University Medical City, Muscat, Oman.
  • Department of Child Health, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.
  • Department of Hematology, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.
  • Department of Pharmacy, The Medical City for Military and Security Services, Muscat, Oman.

ORCID-Profile: Khalid M Al Naamani, Bader Al Rawahi

Zitieren

APA

Al Naamani, K. M., Rizwan, S., Al Sinani, S., Al Rawahi, B., AlMa'mari, S., & El-Kassas, M. (2026). Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296261420229

Vancouver

Al Naamani KM, Rizwan S, Al Sinani S, Al Rawahi B, AlMa'mari S, El-Kassas M. Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice. Clinical and Applied Thrombosis/Hemostasis. 2026. doi:10.1177/10760296261420229

BibTeX
@article{AlNaamani2026,
  author = {Al Naamani, Khalid M and Rizwan, Sundus and Al Sinani, Siham and Al Rawahi, Bader and AlMa'mari, Sheikha and El-Kassas, Mohamed},
  title = {Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  doi = {10.1177/10760296261420229}
}
Kostenlos starten →